Impact of N-acyl piperidine (Piperine) from Piper nigrum on the Pharmacokinetics of CYP3A Substrate Almotriptan in Rats
doi.org/10.26538/tjnpr/v4i8.10
Keywords:
Cytochrome P-450, P-glycoproteinAbstract
Almotriptan belongs to second-generation triptans, which were discovered and developed by Almirall for the treatment of severe migraine headaches. Piperine (N-acyl piperidine) is a plant alkaloid and a natural bioenhancer, which was found to reinforce the bioavailability of structurally and therapeutically different drugs. The study developed a validated highperformance liquid chromatography (HPLC) method for assessment of the pharmacokinetic profile after oral administration of almotriptan (1.2 mg/kg) alone and in combination with Piperine (10 mg/kg) in rats. Pharmacokinetic profile was determined at 0 (predose), 0.5, 1, 1.5,
2, 2.5, 3, 3.5, 4, 6, 9, 12, and 24 hours post-treatment using blood samples. The results indicated that the percentage change of Peak Concentration (Cmax), Maximum Time for maximum concentration (Tmax), Area Under Curve (AUC0-24, AUC0-∞, AUC%) , Area Under Moment Curve (AUMC0-24, AUMC0-∞) , Half-life (T1/2), Mean Residence Time (MRT0-24, MRT0-∞), and volume of distribution (VD) were increased approximately 67.63%, 26.04%, 72.12%, 88.71%, 100.37%, 93.40%, 163.72%, 52.79%, 12.89%, 39.53%, and 25.80%, respectively. In contrast, clearance decreased by 50% when almotriptan was co-administered with Piperine. Piperine significantly improved the fraction of almotriptan that reached the rat's systemic circulation. Therefore, co-administration of piperine improved the bioavailability of almotriptan and could be attributed to the inhibition of CYP3A and P-gp in rats.
References
Accessdata.fda.gov.[Internet] 2020 [cited 06 August 2020].Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021001s008s009lbl.pdf
Taylor F. Acute Treatment of Migraine Headaches. Sem Neurol. 2010; 30(02):145-153.
Galeotti N, Ghelardini C, Grazioli I, Uslenghi C. Indomethacin, caffeine and prochlorperazine alone and combined revert hyperalgesia in in-vivo models of migraine. Pharmacol Res. 2002; 46 (3):245–250.
Mark H and Kim P. Drug Class Review Triptans 4. Oregon Health & Science University. 2009. 5–6 p.
BrandesJL, Buchanan TM, Welch KMA. Acute treatment of migraine. Handbook of Clinical Neurology. Chapter 26.
; 97:323-336.
Srinivasan K. Black pepper and its pungent principlepiperine: a review of diverse physiological effects. Crit Rev
Food Sci Nutr. 2007; 47:735–748.
Meghwal M and Goswami TK. Piper nigrum and piperine: an update. Phytother Res. 2013; 27:1121–1130.
Pattanaik S, Hota D, Prabhakar S, Kharbanda P, Pandhi P. Effect of piperine on the steady-state pharmacokinetics of
phenytoin in patients with epilepsy. Phytother Res. 2006; 20(8):683-686.
Velpandian T, Jasuja R, Bhardwaj R, Jaiswal J, Gupta S. Piperine in food: Interference in the pharmacokinetics of
phenytoin. Eur J Drug Metab Pharmacokin. 2001; 26(4):241-247.
Randhawa GK, Kullar JS, Rajkumar. Bioenhancers from mother nature and their applicability in modern medicine. Int J Appl Basic Med Res. 2011; 1(1):5-10.
Chonpathompikunlert P, Wattanathorn J, Muchimapura S. Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of
Alzheimer’s disease. Food Chem Toxicol. 2010; 48:798– 802.
Rezaee MM, Kazemi S, Kazemi MT, Gharooee S, Yazdani E, Gharooee H, Shiran MR, Moghadamnia AA. The effect
of piperine on midazolam plasma concentration in healthy volunteers, a research on the CYP3A involving metabolism. Daru J Pharm Sci. 2014; 22:8.
Kasibhatta R and Naidu MU. Influence of piperine on the pharmacokinetics of nevirapine under fasting conditions. Drugs Res Dev. 2007; 8:383-391.
Han Y, Chin Tan TM, Lim LY. In vitro and in vivo evaluation of the effects of piperine on P-gp function and expression. Toxicol Appl Pharmacol. 2008; 230:283–289.
Han HK. The effects of black pepper on the intestinal absorption and hepatic metabolism of drugs. Expert Opin
Drug Metab Toxicol. 2011; 7:721–729.
Koul S, Koul JL, Taneja SC, Dhar KL, Jamwal DS, Singh K, Reen RK, Singh J. Structure-activity relationship of
piperine and its synthetic analogues for their inhibitory potentials of rat hepatic microsomal constitutive and
inducible cytochrome P450 activities. Bioorg Med Chem 2000; 8:251–268.
Kim SH and Lee YC. Piperine inhibits eosinophil infiltration and airway hyperresponsiveness by suppressing
T cell activity and Th2 cytokine production in the ovalbumin-induced asthma model. J Pharm Pharmacol. 2009; 61:353–359.
Volak LP, Ghirmai S, Cashman JR, Court MH. Curcuminoids inhibit multiple human cytochromes P450, UDP glucuronosyl transferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos. 2008; 36:1594–1605.
Alhumayyd MS, Bukhari IA, Almotrefi AA. Effect of piperine, a major component of black pepper, on the pharmacokinetics of domperidone in rats. J Physiol harmacol. 2014; 65:785–789.
Jin MJ and Han HK. Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food–drug interaction. J Food Sci. 2010; 75:H93–H96.
Ravikumar K, Chandu BR, Challa BR, Chandrasekhar KB. Method Development and Validation of Almotriptan in
Human Plasma by HPLC Tandem Mass Spectrometry: Application to Pharmacokinetic Study. Scientia Pharm. 2012; 80(2):367-378.
Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-
enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994; 270:414–423.
Johnson WW. Cytochrome P450 inactivation by pharmaceuticals and phytochemicals: therapeutic relevance.
Drug Metab Rev. 2008; 40:101–147.
Kato M. Intestinal first-pass metabolism of CYP3A4 substrates. Drug Metab Pharmacokin. 2008; 23:87–94.
Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 “pie”.
Drug Metab Dispos. 2006; 34:880–886.
Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. Inhibition and induction of human
cytochrome P450 enzymes: current status. Arch Toxicol. 2008; 82:667–715.
Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of
curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J
Pharm Sci. 2009; 37:223-230.
Cho H and Yoon I. Pharmacokinetic Interactions of Herbs with Cytochrome P450 and P-Glycoprotein. Evid-Based
Compl Altern Med. 2015; 2015:1-10.
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Tropical Journal of Natural Product Research (TJNPR)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
